Top Tests After Miscarriage: What to Ask For and When

A miscarriage can leave you with a discharge summary, a few broad reassurances, and the instruction to “try again.” For many patients that is not enough. The right top tests after miscarriage can help separate a one-time chromosomal event from a pattern involving uterine anatomy, hormone signaling, immune activity, metabolism, sperm quality, or cellular energy production.

This is not about searching for a problem where one may not exist. Many first-trimester losses are caused by random chromosome errors in an embryo, and no test prevents every loss. But if you have had more than one loss, are over 35, have struggled to conceive, have irregular cycles, have had a transfer fail, or simply have symptoms that do not fit the “everything is normal” narrative, a deeper look is reasonable. This article walks through what a complete workup can include, what each test can and cannot answer, and when in the cycle to run it.

What tests should I ask for after a miscarriage?

A thorough workup after pregnancy loss usually covers six layers: chromosomal testing of the pregnancy tissue when it is available, imaging of the uterine cavity, a timed hormone and thyroid panel, metabolic labs including fasting insulin, antiphospholipid antibody testing, and a semen analysis with sperm DNA fragmentation for the male partner. Parental karyotypes are added selectively, usually when losses recur or tissue testing suggests an inherited rearrangement. Which of those apply to you depends on your history, your age, and how many losses there have been — the goal is a sequence that answers specific questions, not a panel that generates more data than anyone interprets.

How many losses before a workup makes sense?

Traditional guidance reserves a formal recurrent pregnancy loss evaluation for two or three clinical losses, depending on the practice. The 2022 ESHRE guideline on recurrent pregnancy loss is the most current structured reference for this, and it is notable for how often it recommends against an investigation that is widely sold: of its 62 evidence-based recommendations, only about one in five rests on moderate-quality evidence, and many commonly offered tests did not clear that bar.

That framework is useful, but it is not the whole clinical picture. A 39-year-old with diminished ovarian reserve, autoimmune symptoms, and a loss after an embryo transfer is not in the same situation as a 27-year-old with one early loss and no other fertility concerns. Waiting for a third loss to start looking is a policy, not a diagnosis. If you are earlier in the process and unsure what belongs on a first panel, our guide on when to seek fertility testing covers the baseline.

Why does timing change what the results mean?

Several of these tests are only interpretable in a specific window. Hormone labs need to be anchored to the cycle: a progesterone value means very little without knowing when you ovulated and how many days before the draw that was. Thyroid and prolactin can be transiently shifted by the pregnancy itself, by acute illness, and by stress, so repeating an abnormal value is often more informative than acting on the first one.

After a loss, most of the endocrine workup waits until hCG has returned to zero and a cycle has resumed — we cover that timeline in how long it takes for hCG to clear and your period to return. Antiphospholipid antibodies have their own rule and are discussed below. Imaging of the cavity is typically done after bleeding has stopped, in the first half of the cycle.

Should the pregnancy tissue itself be tested?

If tissue from the pregnancy is available, chromosomal testing of the products of conception is one of the most clarifying places to begin. It answers whether the loss was associated with aneuploidy — an extra or missing chromosome — which is common and becomes more common as egg age rises.

The yield is real. In a series of 2,392 miscarriage specimens under 20 weeks analyzed on a SNP-based chromosomal microarray, results were obtained on 99.9% of samples; among specimens confirmed to be of fetal origin, 59.4% carried a classical cytogenetic abnormality, of which aneuploidy accounted for 85.4% and triploidy 10.3% (Levy and colleagues, Obstetrics & Gynecology, 2014).

A confirmed chromosomal cause may provide real closure, but it does not automatically end the investigation. If losses recur, embryo development has been poor, or there are fertility concerns on both sides, egg, sperm, and the uterine environment still deserve attention. A chromosomally normal loss shifts the conversation toward uterine, immune, clotting, hormonal, and implantation factors.

What does a “normal 46,XX” tissue result actually mean?

This is the single most important caveat in the whole workup, and it is rarely explained. Miscarriage tissue can be contaminated with maternal cells, and when the lab sequences maternal tissue it reports a reassuring normal female result that has nothing to do with the embryo. In the Levy cohort, maternal cell contamination was identified in 22.0% of samples. In a separate review of 1,222 first-trimester specimens, more than half of the normal 46,XX results were maternal rather than fetal; once those were excluded the abnormality rate rose from 48% to 62% (Lathi and colleagues, Fertility and Sterility, 2014).

The practical consequence: ask whether the platform used can detect maternal cell contamination before the sample goes out, and treat a 46,XX result without that check as incomplete rather than normal.

Do both partners need a karyotype?

Parental chromosome analysis is appropriate after recurrent losses, particularly when tissue testing suggests an unbalanced rearrangement or when repeated testing finds no explanation. A small number of couples carry a balanced translocation that does not affect their own health but can affect embryo development.

Scale matters here. In a 16-year series of 2,015 couples investigated for recurrent pregnancy loss, a chromosomal abnormality was found in 3.3% of the 4,030 individuals tested, and 97.7% of those were structural — mostly reciprocal translocations (Aynaci and colleagues, Annals of Saudi Medicine, 2025). That is a meaningful yield in the right population and a poor use of money in the wrong one. When a result is abnormal, it should be interpreted with reproductive genetic counseling, not read off a portal.

How should the uterine cavity be evaluated?

A healthy embryo still needs a cavity that can support implantation and placental development, and congenital anomalies are genuinely more common in this population: roughly 16.7% in women with recurrent miscarriage versus about 6.7% in the general population, in a critical appraisal of the diagnostic literature (Saravelos and colleagues, Human Reproduction Update, 2008). The same review is blunt about method — standard 2D ultrasound and HSG are not accurate enough to diagnose these anomalies, while sonohysterography (a saline infusion sonogram), 3D ultrasound, and hysteroscopy are.

So a routine pelvic ultrasound is a screening tool, not an answer. Depending on your history — prior D&C, cesarean delivery, fibroid surgery, suspected scar tissue, a suspected uterine septum — a saline infusion sonogram, hysteroscopy, or high-quality 3D imaging is what settles the question. Transvaginal ultrasound also tells you about ovarian structure, adenomyosis, endometriosis-related findings, and antral follicle count, and comparing scans over time reveals changes a single scan cannot. When imaging raises the question of pelvic disease behind the losses, our post on when laparoscopy is worth considering in recurrent loss covers that decision.

One honest caveat that most testing articles skip: finding something is not the same as needing it fixed. In an international randomized trial of 80 women with a septate uterus and a history of subfertility, loss, or preterm birth, hysteroscopic septum resection did not improve live birth compared with expectant management (31% versus 35%; Rikken and colleagues, Human Reproduction, 2021). Ask what a given finding would change before agreeing to the procedure that follows it.

Which hormone labs matter, and what does “normal” miss?

A targeted review typically includes TSH, free T4 and free T3, thyroid antibodies, prolactin, AMH, FSH, estradiol, LH, a properly timed progesterone, and androgen markers. The exact panel and its timing should be individualized, and a value inside a reference range is not the same as a value that is optimized for conception. Our walkthrough on how to read fertility labs as a connected system goes through that distinction test by test.

Thyroid deserves its own paragraph because the evidence is strong in one direction and weak in another. A BMJ meta-analysis of 31 studies and 12,126 women found that thyroid autoantibodies in women with normal thyroid function were associated with roughly three to four times the odds of miscarriage (odds ratio 3.90, 95% CI 2.48–6.12; Thangaratinam and colleagues, 2011). That is a strong signal worth testing for. But the TABLET randomized trial then gave levothyroxine to 952 euthyroid women with thyroid peroxidase antibodies and a history of miscarriage or infertility, and live birth was 37.4% on levothyroxine versus 37.9% on placebo (Dhillon-Smith and colleagues, New England Journal of Medicine, 2019). Antibodies are a marker of risk; treating the antibody with thyroid hormone alone did not change the outcome, which is why the finding should redirect attention to the wider autoimmune and metabolic picture rather than end it. More on that in how thyroid function affects fertility.

Where does metabolic testing fit after a loss?

Metabolic dysfunction is one of the most overlooked contributors to reproductive difficulty. You do not need a diabetes diagnosis or a particular body type to have insulin resistance, inflammation, or blood sugar instability affecting ovulation and egg quality — this is why a fasting glucose alone is a weak screen and a normal glucose with a high fasting insulin is such a common miss.

A meaningful metabolic review may include fasting glucose, fasting insulin, hemoglobin A1c, a calculated insulin-resistance index such as HOMA-IR, lipids, liver enzymes, vitamin D, iron studies including ferritin, and body composition. In some cases a glucose challenge with paired insulin measurements shows what fasting values hide.

This matters because reproductive tissue is metabolically expensive. Egg maturation, embryo development, endometrial preparation, and placental formation all run on reliable cellular energy, and mitochondria do that work. When insulin signaling, inflammation, nutrient status, sleep loss, or chronic stress strain that system, the downstream reproductive effect does not show up as an abnormal line on a standard fertility panel.

Which clotting and immune tests are actually established?

Antiphospholipid syndrome is the best-established treatable cause of recurrent pregnancy loss. Testing covers lupus anticoagulant, anticardiolipin antibodies, and anti-beta-2 glycoprotein I antibodies. Persistence is part of the definition: a positive result is confirmed on a repeat sample at least 12 weeks later, and the 2023 ACR/EULAR classification criteria were built specifically for high specificity — meaning a single abnormal value does not make the diagnosis. If you are in the waiting period between draws, our post on a positive lupus anticoagulant while awaiting confirmation explains what that interval does and does not mean.

Inherited thrombophilia panels are a different story. They are ordered broadly, but their role in miscarriage is narrower than the marketing suggests, and treatment has repeatedly failed to deliver: in a randomized trial of 364 women with unexplained recurrent miscarriage, live birth was 54.5% with aspirin plus low-molecular-weight heparin, 50.8% with aspirin alone, and 57.0% with placebo (Kaandorp and colleagues, New England Journal of Medicine, 2010). Testing should follow a personal or family history of clots or pregnancy complications and your physician's judgment, not fear. The same discipline applies to MTHFR variants in recurrent loss, which are far more often tested than they are explanatory.

Immune evaluation needs the same precision. The immune system has two jobs at implantation: defense, and tolerance of the embryo. Autoimmune history, inflammatory symptoms, endometriosis, thyroid antibodies, repeated implantation failure, and unexplained losses can justify a broader review — see how autoimmune activity shows up in recurrent miscarriage and our overview of what immune fertility testing can and cannot tell you. Broad immune claims without clinical context are not a plan; the goal is to find patterns and coordinate with your OB-GYN, reproductive endocrinologist, or rheumatologist.

Does sperm belong in a miscarriage workup?

Yes, and it is routinely left out. Sperm contributes half of the embryo's genome and influences early embryo development, yet a standard semen analysis measures count, motility, and morphology — none of which assess DNA integrity. A meta-analysis of 16 cohort studies covering 2,969 couples found miscarriage roughly twice as likely when sperm DNA damage was high (risk ratio 2.16, 95% CI 1.54–3.03; Robinson and colleagues, Human Reproduction, 2012).

For recurrent loss, poor blastocyst development, unexplained infertility, male age, varicocele, or toxin exposure, DNA fragmentation and oxidative stress testing can find damage a conventional analysis misses — the difference between the two tests is laid out in semen analysis versus sperm DNA fragmentation. A high result does not prove it caused a given loss. It creates a specific and answerable question: why is this sperm DNA under oxidative stress, and what can change before the next attempt?

How do you turn results into a plan?

The most useful evaluation connects the data. It reads lab trends rather than one draw, maps symptoms against the cycle, re-reads imaging, includes both partners, and separates what needs medical treatment or a specialist referral from what responds to focused preconception work. A pile of PDFs from four different labs is not a workup.

At our Huntington clinic this systems-level approach can include metabolic and immune assessment, cervical-vaginal and uterine microbiome testing when clinically appropriate, advanced sperm analysis, and a detailed symptom review across the cycle. Diagnosis and prescribing stay with your OB-GYN or reproductive endocrinologist — what we do is widen the lens, identify modifiable pressure points, and build a plan before another pregnancy asks the body to carry more than it currently can. Patients come to us for this from across Long Island and New York City, often after being told everything looks normal. Our recurrent pregnancy loss support page explains how that work is structured.

If you have been told to keep trying while you are still carrying unanswered questions, you are allowed to ask for a more complete investigation. The next step is not always more testing. Often it is better interpretation, better timing, and a plan built around your specific biology.

This article is general education about testing after pregnancy loss. It is not an interpretation of anyone's individual results, a diagnosis, or medical advice, and it is not a substitute for evaluation with your own clinician.

East to West Fertility is a metabolic and immune-focused fertility clinic in Huntington, Long Island, serving patients across Long Island, NYC, and beyond. Learn more about our Metabolic & Immune Fertility Evaluation or call 631-416-4940.

For a deeper look at the first step, see karyotype vs. microarray testing of miscarriage tissue, including what a "normal female" result can hide.

References:

• ESHRE Guideline Group on RPL, Bender Atik R, Christiansen OB, et al. “ESHRE guideline: recurrent pregnancy loss: an update in 2022.” Human Reproduction Open, 2023;2023(1):hoad002.
• Levy B, Sigurjonsson S, Pettersen B, et al. “Genomic imbalance in products of conception: single-nucleotide polymorphism chromosomal microarray analysis.” Obstetrics & Gynecology, 2014;124(2 Pt 1):202-209. (2,392 specimens.)
• Lathi RB, Gustin SL, Keller J, et al. “Reliability of 46,XX results on miscarriage specimens: a review of 1,222 first-trimester miscarriage specimens.” Fertility and Sterility, 2014;101(1):178-182.
• Aynaci S, Kocagil S, Tosumoglu E, et al. “Chromosomal abnormalities in couples with recurrent pregnancy loss: a 16-year cross-sectional study of 4030 cases from Turkey.” Annals of Saudi Medicine, 2025;45(3):154-164.
• Saravelos SH, Cocksedge KA, Li TC. “Prevalence and diagnosis of congenital uterine anomalies in women with reproductive failure: a critical appraisal.” Human Reproduction Update, 2008;14(5):415-429.
• Rikken JFW, Kowalik CR, Emanuel MH, et al. “Septum resection versus expectant management in women with a septate uterus: an international multicentre open-label randomized controlled trial.” Human Reproduction, 2021;36(5):1260-1267. (80 women randomized.)
• Thangaratinam S, Tan A, Knox E, Kilby MD, Franklyn J, Coomarasamy A. “Association between thyroid autoantibodies and miscarriage and preterm birth: meta-analysis of evidence.” BMJ, 2011;342:d2616. (31 studies, 12,126 women.)
• Dhillon-Smith RK, Middleton LJ, Sunner KK, et al. “Levothyroxine in women with thyroid peroxidase antibodies before conception.” New England Journal of Medicine, 2019;380(14):1316-1325. (TABLET trial, 952 women randomized.)
• Barbhaiya M, Zuily S, Naden R, et al. “The 2023 ACR/EULAR antiphospholipid syndrome classification criteria.” Arthritis & Rheumatology, 2023;75(10):1687-1702.
• Kaandorp SP, Goddijn M, van der Post JA, et al. “Aspirin plus heparin or aspirin alone in women with recurrent miscarriage.” New England Journal of Medicine, 2010;362(17):1586-1596. (364 women randomized.)
• Robinson L, Gallos ID, Conner SJ, et al. “The effect of sperm DNA fragmentation on miscarriage rates: a systematic review and meta-analysis.” Human Reproduction, 2012;27(10):2908-2917. (16 cohort studies, 2,969 couples.)